Meet The Company Giving Patients Access To Unlicensed Medicines
This article was originally published in Scrip
Executive Summary
There is a big unmet need around the ethical management and supply of unlicensed medicines. Their unlicensed status could be due to the products still being experimental, or that the products have been approved in certain territories but not others. And as patients and their physicians become increasingly demanding about access to hard-to-get medicines, a trend which is expected to continue, pharma companies understand they have a responsibility to work with physicians to enable access. And companies such as Clinigen are there to help. Scrip spoke to Clinigen's deputy CEO Shaun Chilton.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.